China News Service, Guangzhou, March 1 (Cai Minjie) As the "king of women's cancer", the mortality rate of ovarian cancer ranks first among gynecological malignancies, and it is also one of the tumors with the highest incidence of gynecological reproductive system.
Yao Shuzhong, director of the Department of Gynecology at the First Affiliated Hospital of Sun Yat-sen University, recently stated that in recent years, in the field of ovarian cancer, with the advent and clinical application of PARP inhibitors, maintenance therapy has become a new standard treatment method that has attracted much attention and has formed " The "surgery + chemotherapy + maintenance treatment" model has enabled ovarian cancer treatment to break through the bottleneck and enter the era of precision treatment.
According to data from the National Cancer Center, the 5-year survival rate for ovarian cancer has only increased by 0.4%, with almost no significant improvement.
In this regard, Yao Shuzhong said: "For a long time, difficult to find, high recurrence, difficult to treat, and poor prognosis are the most prominent problems affecting the survival time of patients with ovarian cancer."
"Ovarian cancer has three cruelty 70% in clinical practice: 70% of patients are at an advanced stage once discovered; 70% of patients will relapse, which means that even after standard surgery and chemotherapy, most patients will still suffer within two years. Recurrence; 70% of patients live less than five years." Yao Shuzhong said that the cause of ovarian cancer is still unclear, and the high incidence is around 40 or 50 years old.
In recent years, in the field of ovarian cancer, with the advent and clinical application of PARP inhibitors, maintenance therapy has become a new standard treatment method and has attracted much attention, especially in patients with platinum-sensitive relapsed ovarian cancer, regardless of whether the patient has BRCA mutation or not. , PARP inhibitor maintenance treatment can prolong progression-free survival and delay recurrence, bringing new hope to ovarian cancer patients and families.
In December last year, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security officially announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" which included 119 drugs, including 17 new anti-cancer drugs, including PD -1. Popular anti-cancer drugs and innovative drugs such as PARP inhibitor niraparib.
It is reported that Nirapali is the only new ovarian cancer drug added to the 2020 drug catalog.
Before being included in the medical insurance catalogue, the average monthly treatment cost for ovarian cancer patients receiving niraparib was about 25,000 yuan; after the inclusion of medical insurance, according to previous years, the proportion of reimbursements for various types of medical insurance in Guangzhou was about 70% to 80%, which means After medical insurance, patients with ovarian cancer who meet the reimbursement conditions use the innovative drug niraparib, and the individual’s out-of-pocket portion only costs 2400 yuan to 3,600 yuan per month.
Yao Shuzhong said: "Now we see that Guangdong is also stepping up the implementation of medical insurance policies, so that more local patients can afford and use preferred anti-tumor drugs. I believe that in the next few years, the standardization and standardization of the treatment of advanced ovarian cancer in the Mainland will be further improved. As a result, the patient’s progression-free survival time and quality of life will also be improved.” (End)